Early and Low Dose Deferasirox (3.5 mg/kg FCT) to Suppress NTBI and LPI as Early Intervention to Prevent Tissue Iron Overload in Lower Risk MDS

NCT03920657 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

11

Enrollment

OTHER

Sponsor class

Stopped enrollment failed

Conditions

Myelodysplastic Syndromes

Interventions

DRUG: Deferasirox

Sponsor

Fondazione Italiana Sindromi Mielodisplastiche-ETS